Novumgen Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 174.58%
- Profit Growth 133.29%
- Ebitda -812.84%
- Net Worth 87.75%
- Total Assets 201.98%
About Novumgen
Novumgen Private Limited (NPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 July 2021 (Three years and six months 9 days old ). Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kamleshkumar Patel, Devalkumar Patel, and Hetalbahen Patel serve as directors at the Company.
Company Details
-
Location
Vadodara, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24299GJ2021PTC124394
-
Company No.
124394
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Jul 2021
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Novumgen?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kamleshkumar Patel | Additional Director | 21-Sep-2024 | Current |
Devalkumar Patel
|
Director | 26-Jul-2021 | Current |
|
Hetalbahen Patel
|
Additional Director | 21-Sep-2024 | Current |
Financial Performance of Novumgen.
Novumgen Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 174.58% increase. The company also saw a substantial improvement in profitability, with a 133.29% increase in profit. The company's net worth Soared by an impressive increase of 87.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novumgen?
In 2023, Novumgen had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Ombit Pharma Private LimitedKamleshkumar Patel and Hetalbahen Patel are mutual person
-
Topia Life Sciences Private Limited
Kamleshkumar Patel and Hetalbahen Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Novumgen?
Novumgen has a workforce of 72 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novumgen, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novumgen's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
